AKT1 and hepatocellular carcinoma: The researchers created a bioactive peptide derived from PCSK9 that acts as a competitive inhibitor of PCSK9 palmitoylation, thereby reducing AKT phosphorylation and boosting the anti‐tumor efficacy of sorafenib in HCC [151].